Therapeutics News and Research

RSS

City of Hope develops adaptive plug-and-play CAR T technology to attack tumors

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer.

22 Sep 2026

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the establishment of a dedicated Alzheimer's Disease Scientific Advisory Board (SAB).

From Galimedix Therapeutics, INC. 22 Sep 2026

New brain circuit discovery offers hope for panic disorder treatments

Our survival depends on brains that constantly search for danger and, if found, stay alert until it has passed.

21 Sep 2026

Stalled gut microbiome development triples risk for type 1 diabetes in children

Type 1 diabetes affects more than 9 million people worldwide, including 1.8 million children and adolescents.

21 Sep 2026

Big Picture Bio founded to identify, design and optimize promising cancer combination therapies

Big Picture Bio Ltd., has been founded to identify, design and optimize promising cancer combination therapies, using a generative world model to understand how tumors, immune cells and surrounding tissue interact across disease sites and patient subgroups.

From Big Picture Bio 18 Sep 2026

Researchers mine cobra toxins to uncover a membrane-disrupting antimicrobial peptide

Researchers combined toxin sequence mining with machine learning and deep-learning prediction tools to identify and experimentally test 14 antimicrobial peptide candidates derived from cobra cardiotoxins. Most candidates showed limited antibacterial potency, while CTX-p5 displayed moderate membrane-disrupting activity, revealing both the potential and current limitations of computationally guided venom peptide discovery.

17 Sep 2026

Salk scientists demonstrate B cells directly enhance killer T cell function

Cancer is the second leading cause of death in the United States, according to a 2026 Cancer Research Institute report. Cancer biologists are keenly aware of this statistic, as it drives them to innovations that revolutionize cancer care-innovations like immunotherapy.

17 Sep 2026

Study defines early-onset cirrhosis caused by fatty liver disease

Researchers at University of California San Diego School of Medicine have published the first study to define early-onset cirrhosis caused by metabolic dysfunction-associated steatotic liver disease (MASLD), a condition known as fatty liver disease.

16 Sep 2026

Study confirms continued effectiveness of antibodies and vaccines used to prevent RSV infections

An analysis of more than 60,000 respiratory syncytial virus (RSV) sequences from around the world found that viral variants associated with resistance to current RSV prevention tools remain rare, according to a study published Sept. 16 in Nature.

16 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

Novel blood test could detect pancreatic cancer at its earliest stages

Researchers at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the country, led the development of a new, investigational blood test that could detect pancreatic cancer at its earliest stages, when the disease is more treatable and potentially curable.

16 Sep 2026

Study illuminates the link between the Epstein-Barr virus and multiple sclerosis

A new study illuminates the connection between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), pointing to a causal role for reactivation of the virus in triggering MS attacks in people with certain genetic risk factors.

16 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

Genetic variant accelerates Huntington’s disease onset by over a decade

A new study has revealed why some people with Huntington disease develop symptoms 10 to 12 years earlier and experience a more aggressive form of the disease.

15 Sep 2026

Optimizing respiratory virus research workflows with VACUBOY

UTS researchers utilize the VACUBOY and VACUSAFE systems to enhance respiratory health studies, streamlining cell culture workflows and improving productivity.

15 Sep 2026

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

15 Sep 2026

Rare cortical neurons actively promote the transition into sleep

What makes the brain fall asleep? For nearly a century, scientists have looked to structures deep within the brain for the answer.

11 Sep 2026

Study shows mRNA vaccines trigger more diverse flu antibody responses

Influenza remains a major global health challenge as continual antigenic drift can limit the breadth and durability of vaccine-induced antibody responses, requiring frequent vaccine updates.

11 Sep 2026

Strength training shows no added arrhythmia risk in people with arrhythmogenic cardiomyopathy

People living with arrhythmogenic cardiomyopathy (ACM), a heritable heart condition that can significantly increase risks for sudden cardiac death, are advised to avoid high-intensity aerobic exercise.

10 Sep 2026

Biolife granted U.S. patent for novel effervescent oral peptide delivery technology

BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease.

10 Sep 2026

Therapeutics News and Research

City of Hope develops adaptive plug-and-play CAR T technology to attack tumors

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

New brain circuit discovery offers hope for panic disorder treatments

Stalled gut microbiome development triples risk for type 1 diabetes in children

Big Picture Bio founded to identify, design and optimize promising cancer combination therapies

Researchers mine cobra toxins to uncover a membrane-disrupting antimicrobial peptide

Salk scientists demonstrate B cells directly enhance killer T cell function

Study defines early-onset cirrhosis caused by fatty liver disease

Study confirms continued effectiveness of antibodies and vaccines used to prevent RSV infections

New AACR report outlines future of cutting-edge cancer research

Novel blood test could detect pancreatic cancer at its earliest stages

Study illuminates the link between the Epstein-Barr virus and multiple sclerosis

Insilico Medicine launches AI initiative to develop longevity vaccines

Genetic variant accelerates Huntington’s disease onset by over a decade

Optimizing respiratory virus research workflows with VACUBOY

Final results from PAPILLON trial confirm long-term survival in a subset of lung cancer

Rare cortical neurons actively promote the transition into sleep

Study shows mRNA vaccines trigger more diverse flu antibody responses

Strength training shows no added arrhythmia risk in people with arrhythmogenic cardiomyopathy

Biolife granted U.S. patent for novel effervescent oral peptide delivery technology

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News